Updates in molecular genetics of acute myeloid leukemia.
暂无分享,去创建一个
[1] G. Garcia-Manero,et al. Consensus proposal for revised International Working Group response criteria for higher risk myelodysplastic syndromes. , 2023, Blood.
[2] A. Porwit,et al. The International Consensus Classification of acute myeloid leukemia , 2022, Virchows Archiv.
[3] B. Ebert,et al. Diagnosis and Management of AML in Adults: 2022 ELN Recommendations from an International Expert Panel. , 2022, Blood.
[4] M. Loh,et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemia: Integrating Morphological, Clinical, and Genomic Data. , 2022, Blood.
[5] Y. Natkunam,et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms , 2022, Leukemia.
[6] T. McDonnell,et al. Pure erythroid leukemia is characterized by biallelic TP53 inactivation and abnormal p53 expression patterns in de novo and secondary cases , 2022, Haematologica.
[7] M. Jongen‐Lavrencic,et al. Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome , 2022, Blood.
[8] Long Su,et al. Acute Myeloid Leukemia With CEBPA Mutations: Current Progress and Future Directions , 2022, Frontiers in Oncology.
[9] P. D. Dal Cin,et al. TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML , 2022, Blood advances.
[10] Dao-bin Zhou,et al. Distinct Mutation Landscapes Between Acute Myeloid Leukemia With Myelodysplasia-Related Changes and De Novo Acute Myeloid Leukemia. , 2021, American journal of clinical pathology.
[11] G. Inghirami,et al. Comparison of Multiple Clinical Testing Modalities for Assessment of NPM1-Mutant AML , 2021, Frontiers in Oncology.
[12] J. Kanda,et al. Prognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemia , 2021, Blood advances.
[13] H. Einsele,et al. CEBPA Mutations in 4708 Patients with Acute Myeloid Leukemia - Differential Impact of bZIP and TAD Mutations on Outcome. , 2021, Blood.
[14] G. Juliusson,et al. Mutational spectrum of de novo NPM1-mutated acute myeloid leukemia patients older than 75 years , 2021, Leukemia & lymphoma.
[15] R. Marasca,et al. NPM1-Mutated Myeloid Neoplasms with <20% Blasts: A Really Distinct Clinico-Pathologic Entity? , 2020, International journal of molecular sciences.
[16] M. Konopleva,et al. Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia. , 2020, Blood advances.
[17] B. Falini,et al. NPM1-mutated acute myeloid leukemia: from bench to bedside. , 2020, Blood.
[18] M. Walter,et al. Genetics of Progression from MDS to Secondary Leukemia. , 2020, Blood.
[19] M. Konopleva,et al. Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens. , 2020, Blood advances.
[20] Benjamin L. Ebert,et al. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes , 2019, Nature Medicine.
[21] T. Haferlach,et al. Molecular Classification of AML-MRC Reveals a Distinct Profile and Identifies MRC-like Patients with Poor Overall Survival , 2019, Blood.
[22] M. Konopleva,et al. NPM1 mutant variant allele frequency correlates with leukemia burden but does not provide prognostic information in NPM1‐mutated acute myeloid leukemia , 2019, American journal of hematology.
[23] W. Wong,et al. Clinicopathologic and genetic characterization of nonacute NPM1-mutated myeloid neoplasms. , 2019, Blood advances.
[24] B. Bain,et al. Morphological and Immunophenotypic Clues to the WHO Categories of Acute Myeloid Leukaemia , 2019, Acta Haematologica.
[25] M. Konopleva,et al. NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy. , 2019, Blood advances.
[26] A. Letai,et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. , 2019, Blood.
[27] G. Del Sal,et al. Mutant p53 as a guardian of the cancer cell , 2018, Cell Death & Differentiation.
[28] W. Hiddemann,et al. NPM1 Variant Allele Frequency and Outcomes in AML , 2018, Blood.
[29] K. Ballman,et al. Somatic mutations precede acute myeloid leukemia years before diagnosis , 2018, Nature Medicine.
[30] Stanley W. K. Ng,et al. Prediction of acute myeloid leukaemia risk in healthy individuals , 2018, Nature.
[31] T. Graubert,et al. High NPM1-mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AML. , 2018, Blood.
[32] C. Preudhomme,et al. NPM1 mutation is not associated with prolonged complete remission in acute myeloid leukemia patients treated with hypomethylating agents , 2018, Haematologica.
[33] C. Bloomfield,et al. Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies , 2018, Leukemia.
[34] Traci M. Blonquist,et al. Association of mutations with morphological dysplasia in de novo acute myeloid leukemia without 2016 WHO Classification-defined cytogenetic abnormalities , 2018, Haematologica.
[35] Wei Li,et al. Mutational spectrum of acute myeloid leukemia patients with double CEBPA mutations based on next-generation sequencing and its prognostic significance , 2018, Oncotarget.
[36] A. Feber,et al. Variable outcome and methylation status according to CEBPA mutant type in double-mutated acute myeloid leukemia patients and the possible implications for treatment , 2017, Haematologica.
[37] A. Tefferi,et al. Nucleophosmin 1 (NPM1) mutations in chronic myelomonocytic leukemia and their prognostic relevance , 2017, American journal of hematology.
[38] M. Konopleva,et al. More than 1 TP53 abnormality is a dominant characteristic of pure erythroid leukemia. , 2017, Blood.
[39] Bob Löwenberg,et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. , 2017, Blood.
[40] S. Miyano,et al. Dynamics of clonal evolution in myelodysplastic syndromes , 2016, Nature Genetics.
[41] Rashmi Kanagal-Shamanna,et al. TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes , 2016, Cancer.
[42] M. Chiarini,et al. CEBPA–double-mutated acute myeloid leukemia displays a unique phenotypic profile: a reliable screening method and insight into biological features , 2016, Haematologica.
[43] U. Jaeger,et al. Karyotype plus NPM1 mutation status defines a group of elderly patients with AML (≥60 years) who benefit from intensive post‐induction consolidation therapy , 2016, American journal of hematology.
[44] W. Hiddemann,et al. Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia. , 2016, Blood.
[45] Nicola D. Roberts,et al. Genomic Classification and Prognosis in Acute Myeloid Leukemia. , 2016, The New England journal of medicine.
[46] J. Merker,et al. Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations , 2015, Modern Pathology.
[47] D. Birnbaum,et al. Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes , 2015, Oncotarget.
[48] D. Neuberg,et al. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. , 2015, Blood.
[49] E. Zeggini,et al. Leukemia-Associated Somatic Mutations Drive Distinct Patterns of Age-Related Clonal Hemopoiesis , 2015, Cell reports.
[50] M. McCarthy,et al. Age-related clonal hematopoiesis associated with adverse outcomes. , 2014, The New England journal of medicine.
[51] T. Haferlach,et al. In AML Secondary to MDS NPM1 Mutations Are Late Events, Less Frequent, and Associated with a Different Pattern of Molecular Mutations Than in De Novo AML , 2014 .
[52] A. Cherry,et al. Acute myeloid leukemia with monosomal karyotype: morphologic, immunophenotypic, and molecular findings. , 2014, American journal of clinical pathology.
[53] Lincoln D. Stein,et al. Identification of pre-leukemic hematopoietic stem cells in acute leukemia , 2014, Nature.
[54] I. Weissman,et al. Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission , 2014, Proceedings of the National Academy of Sciences.
[55] M. Stratton,et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. , 2013, Blood.
[56] C Haferlach,et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes , 2013, Leukemia.
[57] L. Bullinger,et al. Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia. , 2013, Blood.
[58] Yuehua Wu,et al. Clinicopathologic analysis of acute myeloid leukemia arising from chronic myelomonocytic leukemia , 2013, Modern Pathology.
[59] Benjamin J. Raphael,et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. , 2013, The New England journal of medicine.
[60] Je-Hwan Lee,et al. Association of cup-like nuclei in blasts with FLT3 and NPM1 mutations in acute myeloid leukemia , 2013, Annals of Hematology.
[61] Joshua F. McMichael,et al. The Origin and Evolution of Mutations in Acute Myeloid Leukemia , 2012, Cell.
[62] D. Birnbaum,et al. Acute myeloid leukemia with myelodysplasia‐related changes are characterized by a specific molecular pattern with high frequency of ASXL1 mutations , 2012, American journal of hematology.
[63] N. Socci,et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. , 2012, The New England journal of medicine.
[64] U. Moll,et al. Links between mutant p53 and genomic instability , 2012, Journal of cellular biochemistry.
[65] K. Döhner,et al. Monosomal karyotype in adult acute myeloid leukemia: prognostic impact and outcome after different treatment strategies. , 2012, Blood.
[66] J. Esteve,et al. Immunophenotype of acute myeloid leukemia with NPM mutations: prognostic impact of the leukemic compartment size. , 2011, Leukemia research.
[67] J. Esteve,et al. The prognostic value of multilineage dysplasia in de novo acute myeloid leukemia patients with intermediate-risk cytogenetics is dependent on NPM1 mutational status. , 2010, Blood.
[68] J. Licht,et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. , 2010, Cancer cell.
[69] R. Hills,et al. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[70] Paola Fazi,et al. Multilineage dysplasia has no impact on biologic, clinicopathologic, and prognostic features of AML with mutated nucleophosmin (NPM1). , 2010, Blood.
[71] E. Hoster,et al. Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[72] K Holzmann,et al. Identification of acquired copy number alterations and uniparental disomies in cytogenetically normal acute myeloid leukemia using high-resolution single-nucleotide polymorphism analysis , 2010, Leukemia.
[73] Bas J. Wouters,et al. Brief Report Results and Discussion , 2022 .
[74] T. Pabst,et al. Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosis , 2009, British Journal of Cancer.
[75] A. Hagemeijer,et al. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[76] Axel Benner,et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. , 2008, The New England journal of medicine.
[77] R. Arceci,et al. The incidence and clinical significance of nucleophosmin mutations in childhood AML. , 2007, Blood.
[78] Brunangelo Falini,et al. Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features. , 2007, Blood.
[79] E. Hoster,et al. NPM1 but not FLT3-ITD mutations predict early blast cell clearance and CR rate in patients with normal karyotype AML (NK-AML) or high-risk myelodysplastic syndrome (MDS). , 2006, Blood.
[80] Myriam Alcalay,et al. Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia. , 2006, Blood.
[81] B. Cheson,et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. , 2006, Blood.
[82] Pier Paolo Pandolfi,et al. Nucleophosmin and cancer , 2006, Nature Reviews Cancer.
[83] W. Hiddemann,et al. Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML. , 2006, Blood.
[84] D. Steensma,et al. C‐terminal nucleophosmin mutations are uncommon in chronic myeloid disorders , 2006, British journal of haematology.
[85] Bob Löwenberg,et al. Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. , 2005, Blood.
[86] P. Pandolfi,et al. Role of nucleophosmin in embryonic development and tumorigenesis , 2005, Nature.
[87] Paola Fazi,et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. , 2005, The New England journal of medicine.
[88] C. Nerlov. C/EBPα mutations in acute myeloid leukaemias , 2004, Nature Reviews Cancer.
[89] L. Shih,et al. Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia , 2004, Leukemia.
[90] S. Fröhling,et al. CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[91] J. Cayuela,et al. Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). , 2002, Blood.
[92] N. Harris,et al. The World Health Organization (WHO) classification of the myeloid neoplasms. , 2002, Blood.
[93] J. Griffin,et al. The roles of FLT3 in hematopoiesis and leukemia. , 2002, Blood.
[94] S. Fröhling,et al. Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics: a study of the Acute Myeloid Leukemia Study Group Ulm. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[95] Pier Giuseppe Pelicci,et al. Nucleophosmin regulates the stability and transcriptional activity of p53 , 2002, Nature Cell Biology.
[96] D. Grimwade,et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. , 2001, Blood.
[97] T. Naoe,et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. , 2001, Blood.
[98] Pu Zhang,et al. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-α (C/EBPα), in acute myeloid leukemia , 2001, Nature Genetics.
[99] H. Kaneko,et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. , 1996, Leukemia.
[100] W. Hiddemann,et al. De novo AML with dysplastic hematopoiesis: cytogenetic and prognostic significance. , 1996, Leukemia.
[101] M. Caligiuri,et al. Molecular rearrangement of the ALL-1 gene in acute myeloid leukemia without cytogenetic evidence of 11q23 chromosomal translocations. , 1994, Cancer research.
[102] G Flandrin,et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. , 1985, Annals of internal medicine.
[103] H. Gralnick,et al. Proposals for the Classification of the Acute Leukaemias French‐American‐British (FAB) Co‐operative Group , 1976, British journal of haematology.
[104] M. Olson,et al. Phosphorylation of acid-soluble proteins in isolated nucleoli of Novikoff hepatoma ascites cells. Effects of divalent cations. , 1974, The Journal of biological chemistry.
[105] C. Chao. Mechanisms of p53 degradation. , 2015, Clinica chimica acta; international journal of clinical chemistry.
[106] S. Fröhling,et al. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. , 2012, Blood.
[107] L. Medeiros,et al. FLT3 and NPM1 mutations in myelodysplastic syndromes: Frequency and potential value for predicting progression to acute myeloid leukemia. , 2011, American journal of clinical pathology.
[108] M. Yao,et al. Clinical and biological implications of partial tandem duplication of the MLL gene in acute myeloid leukemia without chromosomal abnormalities at 11q23 , 2002, Leukemia.